Affiliations 

  • 1 Department of Global Health and Population, Harvard T H Chan School of Public Health, Boston, MA, USA; Faculty of Medicine, Imperial College London, London, UK. Electronic address: ratun@hsph.harvard.edu
  • 2 Vedanta Medical Research Foundation, Balco Medical Centre, Raipur, Chhattisgarh, India
  • 3 Department of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • 4 Guy's Cancer Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK; Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
  • 5 Department of Radiotherapy and Oncology, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
  • 6 Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
  • 7 Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands
  • 8 Department of Global Health and Population, Harvard T H Chan School of Public Health, Boston, MA, USA
  • 9 The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia
  • 10 Department of Surgery, The Royal Marsden NHS Foundation Trust, London, UK; Dow University of Health Sciences, Karachi, Pakistan
  • 11 Department of Surgery and Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
  • 12 School of Electronics and Computer Science, University of Southampton, Southampton, UK
  • 13 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
  • 14 Velindre Cancer Centre, Velindre University NHS Trust, Cardiff, UK
  • 15 Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
  • 16 Department of Public Health, University of Otago, Wellington, New Zealand
  • 17 Faculty of Medicine, University of Southampton, Southampton, UK
  • 18 Department of Noncommunicable Diseases, WHO, Geneva, Switzerland
  • 19 Division of Head and Neck Oncology and Reconstructive Surgery, Department of Otolaryngology-Head and Neck Surgery, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
  • 20 Faculty of Medicine, University of Otago, Dunedin, New Zealand
  • 21 Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
  • 22 Union for International Cancer Control, Geneva, Switzerland
  • 23 Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Escuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey, Facultad de Excelencia, Mexico City, Mexico; Tómatelo a Pecho, Mexico City, Mexico; Fundación Mexicana para la Salud, Mexico City, Mexico
  • 24 UK and Ireland Global Cancer Network, Oxford, UK
  • 25 Department of Surgery, Aga Khan University Hospital, Nairobi, Kenya
  • 26 African Center for Research on End-of-Life Care, Kigali, Rwanda
  • 27 WifOR Institute, Darmstadt, Germany
  • 28 Tata Memorial Hospital, Mumbai, India; National Cancer Grid, Mumbai, India; Homi Bhabha National Institute, Mumbai, India
  • 29 Department of Child Health, University of Ghana Medical School, University of Ghana, Accra, Ghana
  • 30 Medicaid Cancer Foundation, Abuja, Nigeria
  • 31 International Agency for Research on Cancer, Lyon, France
  • 32 Faculty of Medical Sciences, The University of the West Indies, Kingston, Jamaica
  • 33 Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton, UK; Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK
  • 34 National Cancer Audit Collaborating Centre, Royal College of Surgeons of England, London, UK
  • 35 Lymphoma Coalition, Etobicoke, ON, Canada
  • 36 Department of Global Health and Population, Harvard T H Chan School of Public Health, Boston, MA, USA; Center for Health Decision Science, Department of Health Policy and Management, Harvard T H Chan School of Public Health, Boston, MA, USA
  • 37 Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 38 The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia; School of Clinical Medicine, UNSW Sydney, Sydney, NSW, Australia; The Collaboration for Cancer Outcomes, Research and Evaluation, Ingham Institute, Liverpool, NSW, Australia; Department of Radiation Oncology, South Western Sydney Local Health District, Liverpool, NSW, Australia; School of Medicine, Western Sydney University, Campbelltown, NSW, Australia
Lancet Oncol, 2026 Nov 04.
PMID: 42982064 DOI: 10.1016/S1470-2045(26)00396-7

Abstract

Cancer is now one of the defining health and development challenges of our time. The 56 nations of the Commonwealth, home to 2·7 billion people, mirror this global burden. Recorded cancer cases across member states rose by 35% in 2008-18 and the number of deaths reached almost 1·7 million in 2018. The Lancet Oncology Commission on cancer in the Commonwealth was convened to ask a deceptively simple question: how can 56 diverse nations act collectively to close the widening gap between the burden of cancer and the capacity of each country to respond? 80 researchers, clinicians, policy makers, and civil society members, organised into five working groups and ten research streams, spent 2 years assembling the evidence base for this report. Using a validated microsimulation model, we estimate that 5-year net survival across eleven common cancers in the Commonwealth stood at just 30·7% in 2020, ranging from 4·1% in low-income countries (LICs) to 59·0% in high-income countries (HICs), driven overwhelmingly by late-stage presentation, which affects 62% of patients in LICs compared with 43% in HICs. This difference in survival is compounded by chronic underinvestment. Infrastructure gaps are equally stark: only 12% of countries meet international benchmarks for CT imaging, 22% for hospital density, and 40% for radiotherapy. Governance is underdeveloped too: barely one-third of Commonwealth countries have a national cancer control plan meeting basic quality criteria. Research investment also mirrors these inequities: between 2016 and 2023, Commonwealth countries collectively invested only US$165 per cancer-related disability adjusted life year. Yet the case for investment is unambiguous. Our modelling shows that a comprehensive scaleup of treatment, imaging, and quality of care could raise 5-year net survival across the Commonwealth from 30·7% to 52·9%, averting an estimated 5·8 million deaths and adding 113 million life-years between 2025 and 2035, at an incremental cost of $36·7 billion, delivering a return of between four and twenty dollars on every dollar invested. Crucially, this investment need not depend chiefly on external aid, which is contracting sharply at present. Our modelling for 38 low-income and middle-income Commonwealth countries suggests that up to $701 billion in additional domestic fiscal space could be mobilised between 2025 and 2030, through budget reprioritisation, macroeconomic growth, targeted taxation, and prudent borrowing. On this evidence, the Commission proposes six priority actions. These commitments are ambitious, set against an unusually turbulent geopolitical backdrop of declining official development assistance, fiscal retrenchment, and contested multilateralism. Yet it is precisely this backdrop that gives the Commonwealth its distinctive advantage: a voluntary association spanning every income level and continent, bound by common legal and regulatory traditions, capable of collective action that neither purely bilateral aid nor multilateral institutions under strain can easily replicate.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.